§ 1271.60. What quarantine and other requirements apply before the donor-eligibility determination is complete?

402 words·~2 min read·/us/cfr/t21/s§ 1271.60·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

(a)Quarantine. You must keep an HCT/P in quarantine, as defined in § 1271.3(q), until completion of the donor-eligibility determination required by § 1271.50. You must quarantine semen from anonymous donors until the retesting required under § 1271.85(d) is complete.

(b)Identification of HCT/Ps in quarantine. You must clearly identify as quarantined an HCT/P that is in quarantine pending completion of a donor-eligibility determination. The quarantined HCT/P must be easily distinguishable from HCT/Ps that are available for release and distribution.

(c)Shipping of HCT/Ps in quarantine. If you ship an HCT/P before completion of the donor-eligibility determination, you must keep it in quarantine during shipment. The HCT/P must be accompanied by records:

(1)Identifying the donor (e.g., by a distinct identification code affixed to the HCT/P container);

(2)Stating that the donor-eligibility determination has not been completed; and

(3)Stating that the product must not be implanted, transplanted, infused, or transferred until completion of the donor-eligibility determination, except under the terms of paragraph

(d)of this section.

(d)Use in cases of urgent medical need.

(1)This subpart C does not prohibit the implantation, transplantation, infusion, or transfer of an HCT/P from a donor for whom the donor-eligibility determination is not complete if there is a documented urgent medical need for the HCT/P, as defined in § 1271.3(u).

(2)If you make an HCT/P available for use under the provisions of paragraph (d)(1) of this section, you must prominently label it “NOT EVALUATED FOR INFECTIOUS SUBSTANCES,” and “ WARNING: Advise patient of communicable disease risks.” The following information must accompany the HCT/P:

(i)The results of any donor screening required under § 1271.75 that has been completed;

(ii)The results of any testing required under § 1271.80 or 1271.85 that has been completed; and

(iii)A list of any screening or testing required under § 1271.75, 1271.80 or 1271.85 that has not yet been completed.

(3)If you are the establishment that manufactured an HCT/P used under the provisions of paragraph (d)(1) of this section, you must document that you notified the physician using the HCT/P that the testing and screening were not complete.

(4)In the case of an HCT/P used for an urgent medical need under the provisions of paragraph (d)(1) of this section, you must complete the donor-eligibility determination during or after the use of the HCT/P, and you must inform the physician of the results of the determination.

Connections2 cite this

Cited by 2 sections

Citation graph

cites case law

§ 1271.60

What quarantine and other requirements apply before the donor-eligibility determination is complete?

Fed. Reg.×2

Cites 0Cited by 2 across 1 source